Structure Therapeutics (NASDAQ: GPCR) experienced a significant surge in its stock price, jumping more than 99% to approximately $68.84. This sharp increase followed the company's announcement of successful Phase 2 clinical data for aleniglipron, its investigational once-daily oral treatment designed for managing body weight and metabolic health.
ACCESS Phase 2b Results Boost Investor Confidence
Structure Therapeutics announced that its Phase 2b ACCESS trial successfully met all primary and secondary goals, demonstrating strong statistical results. The study involved approximately 230 adults who were living with higher body weight and had related health conditions.
Participants administered up to a 120 mg dose consistently showed reductions in body weight. Specifically, the highest-dose group achieved an average placebo-adjusted decrease of 11.3% over a 36-week period, which equates to an average reduction of about 27 pounds.
Approximately 70% of participants in the highest dose group experienced a body weight reduction of more than 10%, indicating a clear dose-response pattern. Researchers also reported improvements in blood pressure and HbA1c levels, suggesting broader metabolic benefits beyond weight management.
The reported side effects were primarily gastrointestinal in nature. These effects tended to manifest early in treatment and subsequently improved over time. The average discontinuation rate across all active treatment groups was around 10.4%, which is considered manageable and comparable to rates observed with other GLP-1 treatments.
ACCESS II Shows Additional Promise at Higher Doses
The more recent ACCESS II study evaluated even higher doses of aleniglipron, up to 240 mg, in a cohort of 85 adults living with higher body weight. This study observed a greater reduction in body weight with the higher administered doses. The top dose group achieved a placebo-adjusted decrease of 15.3% (approximately 35.5 pounds), also measured at Week 36.
Importantly, researchers noted that the treatment effect had not yet reached a plateau, suggesting that weight-related outcomes continued to improve beyond the study's timeframe. Safety signals remained consistent with previous findings, and the overall safety profile appeared similar across all tested doses.
Supporting Research Shows Flexibility for Future Dosing
Structure Therapeutics also presented early findings from a body-composition study that utilized a gradual titration approach, starting at a dose of 2.5 mg. Notably, no participants discontinued treatment early during the initial phases of this study, which supports the viability of a slower dosing ramp-up strategy for real-world clinical application.
The ongoing study and its extension phase are designed to track longer-term results. Early indications from these ongoing assessments suggest that treatment benefits continue to progress beyond the 36-week mark.